Peter B. Hesseling

Peter B. Hesseling

Auto-generated profile, based on publicly available information

Peter B. Hesseling

Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences Stellenbosch University and Tygerberg Hospital Cape Town South Africa

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2004 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
PHPeter Hesseling
Peter Hesseling
RBRobin Broadhead
Robin Broadhead
EMErna Mansvelt
Erna Mansvelt
MLMercia Louw
Mercia Louw
GWGlynn Wessels
Glynn Wessels
EMElizabeth Molyneux
Elizabeth Molyneux

28 November 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
PHPeter Hesseling
Peter Hesseling
TITrijn Israels
Trijn Israels
MHMhamed Harif
Mhamed Harif
GCGuillermo Chantada
Guillermo Chantada
EMElizabeth Molyneux
Elizabeth Molyneux

24 October 2003 in Medical and Pediatric Oncology
Verified
Journal Article
Closed access
PDF file
PHPeter B. Hesseling
Peter B. Hesseling
RBRobin Broadhead
Robin Broadhead
EMElizabeth Molyneux
Elizabeth Molyneux
EBEric Borgstein
Eric Borgstein
JSJohann W. Schneider
Johann W. Schneider
GWGlynn Wessels
Glynn Wessels

1 March 2009 in Paediatrics and International Child Health
Verified
Journal Article
Closed access
PHP. Hesseling
P. Hesseling
EME. Molyneux
E. Molyneux
SKS. Kamiza
S. Kamiza
TIT. Israels
T. Israels
RBR. Broadhead
R. Broadhead
Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and there is a need for affordable, effective treatment. To record the morbidity of treatment and event-free survival after 1 year using relatively high doses of cyclophosphamide at short intervals combined with intrathecal methotrexate. Forty consecutive patients with a mean age of 6.9 (range 2-15) years were treated at Queen Elizabeth Central Hospital, Blantyre between 10th April and 17th November 2006. The initial diagnosis was made clinically and confirmed by fine-needle aspiration in 73%. Abdominal ultrasound, bone marrow aspirate and CSF analysis were undertaken routinely. Chemotherapy consisted of cyclophosphamide, 40 mg/kg on day 1 and 60 mg/kg on days 8, 18 and 28. Intrathecal methotrexate 12.5 mg and hydrocortisone 12.5 mg were administered on days 1, 8, 18 and 28. Allopurinol was commenced before chemotherapy, and a high urinary output was maintained to prevent tumour lysis. St Jude stage distribution was stage I, 1; II, 9; III, 24; and IV, 6. An equal number (70%) presented with abdominal and facial disease, and 15% with paraplegia. Twenty patients (50%) were below the 5th NCHS centile for weight-for-age. Two patients died during treatment, three had chemotherapy-resistant disease and 35 (88%) achieved complete clinical remission by day 28. Sixteen required antibiotic treatment for presumed infection and nine received a blood transfusion. Relapse occurred in 16 patients after 65-311 days (median 137). Nineteen patients (48%) have been in continued remission for 265-670 days (median 454). This short, inexpensive treatment schedule (<50 US$) cured almost 50% of eBL patients in a setting of very limited resources.

24 February 2012 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
PHP. B. Hesseling
P. B. Hesseling
ENE. Njume
E. Njume
FKF. Kouya
F. Kouya
TKT. Katayi
T. Katayi
PWP. Wharin
P. Wharin
PMP. McCormick
P. McCormick
Treatment of endemic Burkitt lymphoma (BL) with cyclophosphamide (CPM) and intrathecal methotrexate (IT MTX) can cure 50% of patients. In this study, induction therapy with CPM and IT MTX was followed by consolidation chemotherapy adapted for stage, clinical response, and abdominal ultrasound findings. One hundred and twenty-nine consecutive patients with BL, 77 male and 52 female with a median age of 7.9 years, were treated in mission hospitals in Cameroon. The diagnosis rested on fine-needle aspirate (79%), biopsy, bone marrow, cerebrospinal fluid, abdominal ultrasound, and clinical examination. Six percent had St Jude stage I, 13% stage II, 72% stage III, and 12% stage IV disease. The abdomen (76%) and face (50%) were mainly involved. Induction chemotherapy was CPM 40 mg/kg and IT MTX 12.5 mg and IT hydrocortisone 12.5 mg on days 1, 8, and 15. Stage I and II patients received CPM 60 mg/kg on day 29, and stage III patients CPM 60 mg/kg on days 29 and 43 if in remission on day 28. Stage IV patients and patients not in remission received CPM 60 mg/kg on days 29, 43, and 57 and 1.0 g/m2 MTX intravenous (IV) and vincristine 1.5 mg/m2 IV on day 29. Event-free survival (EFS) at mean 365 days was 61% (n = 79) and 100% in stage I, 85% in stage II, 60% in stage III, and 27% in stage IV patients. Deaths (n = 24) were disease or treatment related and 26 patients relapsed (mean 135 days). Risk-adapted treatment achieved 61% 1-year EFS.

30 July 2013 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
TITrijn Israëls
Trijn Israëls
JKJoyce Kambugu
Joyce Kambugu
FKFrancine Kouya
Francine Kouya
NENader Kim El-Mallawany
Nader Kim El-Mallawany
PHPeter B. Hesseling
Peter B. Hesseling
EMElizabeth M. Molyneux
Elizabeth M. Molyneux